Timesulin

Timesulin, operating under its parent company Patients Pending Ltd, was founded in 2010 to address a critical need in diabetes management. The company's inception was driven by the personal experiences of co-founder John Sjölund, who has lived with Type 1 diabetes since he was four years old. Sjölund frequently faced the anxiety of not remembering if he had taken his insulin injection, a common issue for many of the millions of individuals who rely on daily insulin. This personal struggle led him to collaborate with his brother, Andreas Sjölund (a co-creator of Skype), and Marcel Botha, an entrepreneur and engineer, to create a simple solution to a widespread problem.

The company's flagship product is the Timesulin replacement cap, a device designed for simplicity and seamless integration into a user's routine. It is a smart cap for insulin pens that features a built-in timer, which automatically starts counting up from zero the moment it is placed back on the pen after an injection. This core function directly addresses the risk of missed or accidental double doses of insulin, which can lead to dangerous high or low blood glucose levels. The cap is designed to fit all major insulin pens, requires no complex setup, and operates on a non-replaceable battery with a one-year lifespan, after which the unit is replaced. The product gained CE certification as a Class 1 medical device, allowing for its commercialization. [ ]

The business model centered on direct-to-consumer sales through its website and a network of independent distributors and pharmacists. [ ] With manufacturing based in Germany, the company established a global presence, selling its products in over 40 countries to hundreds of thousands of users. In June 2017, Patients Pending Ltd, and with it the Timesulin brand, was acquired by Bigfoot Biomedical, Inc. The acquisition was a strategic move for Bigfoot to integrate Timesulin's connected pen cap technology into its broader ecosystem of automated insulin delivery systems. Following the acquisition, John Sjölund joined the Bigfoot Biomedical team to continue his work on advancing diabetes technology for those who use insulin injections. The Timesulin product line has since been discontinued as the parent company's focus has shifted.

Keywords: diabetes management, insulin pen cap, medication adherence, smart cap, medtech, diabetic device, insulin timer, glucose monitoring, Patients Pending Ltd, Bigfoot Biomedical, John Sjölund, Andreas Sjölund, Marcel Botha, insulin injection tracker, chronic condition management, digital health, medical device, hypo, hyperglycemia, CE certified medical device